TrialAnnals of the rheumatic diseases2014

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.

Michael Schiff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.